Status:
COMPLETED
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
Eligibility Criteria
Inclusion
- Postmenopausal women with early hormone receptor positive breast cancer/no metastasis
Exclusion
- None
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT00638391
Start Date
May 1 2005
End Date
March 1 2007
Last Update
March 20 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.